Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2006

Filing Date
Filed February 9, 2007
Period End
December 31, 2006
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 9, 2007. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. is a Delaware corporation that discovers and intends to commercialize drugs for neurological and endocrine-related diseases.

Its lead product candidate, indiplon for insomnia, received two complete responses from the FDA on May 15, 2006: indiplon 5 mg and 10 mg capsules were deemed approvable, while the 15 mg tablets were deemed not approvable. The company plans to resubmit the capsule NDA by the end of the second quarter of 2007, and is evaluating a sleep maintenance claim for both formulations. Following the termination of its Pfizer collaboration effective December 19, 2006, Neurocrine reacquired all worldwide rights to indiplon and is responsible for its future costs; it will seek a new partner at an appropriate time.

Financially, total revenues fell to $39.2 milliona in 2006 from $123.9 million in 2005, mainly because 2005 included $70.0 million in Pfizer milestones. The net loss widened to $107.2 million, or $2.84 per share, from $22.2 million in 2005. The accumulated deficit reached $407.4 million, and cash, cash equivalents and short-term investments totaled $182.6 million at year-end, down from $273.1 million.

The company expects revenues and SG&A to decrease significantly in 2007, expects to use about $80.0 millionb of cash in 2007, and expects to end the year with at least $100.0 million. It states that it does not expect to be profitable in 2007 and that its existing resources should suffice for at least the next 12 months.

The company also restructured in 2006: it terminated its 200-person sales force in July 2006 and cut about 100 San Diego R&D and G&A positions in August 2006, recording a charge of about $9.5 millionc. Pipeline programs include a GnRH antagonist for endometriosis in Phase II/IIb, a CRF R1 antagonist partnered with GlaxoSmithKline (now in Phase II for social anxiety disorder and irritable bowel syndrome), urocortin 2 for congestive heart failure in Phase II, and a selective norepinephrine reuptake inhibitor for neuropathic pain in Phase I.

Key Highlights

  1. Indiplon (insomnia): FDA issued an Approvable Letter for 5 mg and 10 mg capsules and a Not Approvable Letter for 15 mg tablets on May 15, 2006; capsule NDA resubmission is targeted by end of Q2 2007.
  2. Pfizer collaboration terminated effective December 19, 2006; Neurocrine reacquired all worldwide rights to indiplon and bears its future development and commercialization costs.
  3. 2006 total revenues were $39.2 million versus $123.9 million in 2005, primarily reflecting $70.0 million in 2005 Pfizer milestones.
  4. Net loss of $107.2 million ($2.84 per share) in 2006, compared with $22.2 million ($0.60 per share) in 2005; accumulated deficit of $407.4 million.
  5. Cash, cash equivalents and short-term investments were $182.6 million at December 31, 2006, and the company expects to use about $80.0 million in 2007 and end the year with at least $100.0 million.
  6. Restructuring in 2006 terminated the entire sales force and eliminated about 100 San Diego positions, with a one-time charge of approximately $9.5 million; the company expects this to reduce expenses by about $50.0 million in 2007.
  7. Pipeline: nine programs, six in clinical development, including a GnRH antagonist (Phase II for endometriosis), a CRF R1 antagonist partnered with GlaxoSmithKline, urocortin 2 (Phase II), and an sNRI (Phase I).

Frequently Asked Questions

  1. What is the status of the FDA review for indiplon?

    On May 15, 2006, the FDA issued an Approvable Letter for indiplon 5 mg and 10 mg capsules and a Not Approvable Letter for 15 mg tablets. Neurocrine held end-of-review meetings in August and October 2006 and is targeting resubmission of the capsule NDA by the end of the second quarter of 2007. For the tablets, the FDA requested additional long-term safety and efficacy data at the 15 mg dose and a separate elderly dose, and the company is evaluating a sleep maintenance claim.

  2. Why did revenues decline so sharply in 2006?

    Revenues were $39.2 million in 2006 versus $123.9 million in 2005. The filing attributes the decline primarily to milestones recognized in 2005 under the Pfizer agreement, including $70.0 million related to the FDA's acceptance for review of the indiplon NDAs. The company expects revenues to decrease significantly again in 2007 because of the cancellation of the Pfizer agreement.

  3. How much cash does the company have, and how long will it last?

    Cash, cash equivalents and short-term investments totaled $182.6 million at December 31, 2006, down from $273.1 million a year earlier. The company expects to use approximately $80.0 million in 2007 and end the year with at least $100.0 million. It believes existing resources, together with interest income and future alliance payments, will be sufficient for at least the next 12 months, but says it may need additional funding and that equity financing would be dilutive.

  4. Who will commercialize indiplon now that Pfizer has exited?

    Neurocrine reacquired all worldwide rights to indiplon effective December 19, 2006, and is responsible for related costs. The company says it will seek a partner at an appropriate time for worldwide development and commercialization, or else commercialize indiplon itself, which would require building a sales infrastructure. It notes competition in finding a partner and that it terminated its sales force in July 2006.

  5. Does the company expect to be profitable?

    No. The filing states that the company does not expect to be profitable in 2007 and has an accumulated deficit of $407.4 million. It expects to incur operating losses in the near future, which may be greater than prior years' losses, and says it may never achieve sustained profitability.